BriaCell Therapeutics (TSE:BCT) Stock Price Up 0.9% – What’s Next?

BriaCell Therapeutics Corp. (TSE:BCT)’s share price traded up 0.9% on Thursday . The stock traded as high as C$5.77 and last traded at C$5.73. 23,384 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 43,565 shares. The stock had previously closed at C$5.68.

BriaCell Therapeutics Stock Up 0.9%

The firm has a 50-day simple moving average of C$10.37 and a 200 day simple moving average of C$12.16. The company has a market cap of C$35.59 million, a price-to-earnings ratio of -0.17 and a beta of 2.15.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.